TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22595172

Group type: EXPERIMENTAL
Intervention: Kangaroo Care 30 minutes (KC30)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Kangaroo Care 15 minutes (KC15)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Incubator Care (IC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All conditions (KC30, KC15, IC)
Number of subjects: 26
Study: 19246508

Group type: EXPERIMENTAL
Intervention: Esomeprazole, bismuth subcitrate, tetracycline and metronidazole (EBTM)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Esomeprazole, amoxicillin and levofloxacin (EAL)
Number of subjects: 166

Group type: COMPARATOR
Intervention: EBTM
Number of subjects: 166

Group type: COMPARATOR
Intervention: EAL
Number of subjects: 166
Study: 17478453

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (group US, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nerve stimulation guidance (group NS, n = 30)
Number of subjects: 60
Study: 15067189

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance method for predicting total body water (TBW)
Number of subjects: 70
Study: 12565715

Group type: EXPERIMENTAL
Intervention: Warfarin (2 mg per day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 103
Study: 9514421

Group type: EXPERIMENTAL
Intervention: Oophorectomy
Number of subjects: 155

Group type: COMPARATOR
Intervention: Nonoophorectomy
Number of subjects: 155
Study: 7822572

Group type: EXPERIMENTAL
Intervention: Postconditioning rehearsal of the unconditioned stimulus (UCS) in subjects with high levels of trait anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postrehearsal in subjects with induced somatic anxiety
Number of subjects: 0

Group type: COMPARATOR
Intervention: Induced worrying or neutral induction procedure
Number of subjects: 0
Study: 3046414

Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.1 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 20
Study: 31353988

Group type: EXPERIMENTAL
Intervention: Rational-emotive behaviour therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Counselling (Control)
Number of subjects: 23
Study: 29380761

Group type: EXPERIMENTAL
Intervention: Optisol-GS preservative medium (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transfer from MK medium to Optisol-GS (Group B)
Number of subjects: 20
Study: 28329434

Group type: EXPERIMENTAL
Intervention: COPE treatment (Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure)
Number of subjects: 31
Study: 25691362

Group type: EXPERIMENTAL
Intervention: Visual feedback overstating true rotation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Visual feedback understating true rotation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Accurate visual feedback
Number of subjects: 24
Study: 23078045

Group type: EXPERIMENTAL
Intervention: Achieve catheter (AC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (single transseptal approach)
Number of subjects: 32
Study: 20601736

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF; 3.7 mg/kg BM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Carbohydrate (CON; 1.8 g/kg BM)
Number of subjects: 15
Study: 18410762

Group type: EXPERIMENTAL
Intervention: OGTT (Oral Glucose Tolerance Test)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Boost test (liquid mixed-meal test)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hyperglycemic clamp test (Hyper-C)
Number of subjects: 26
Study: 16637728

Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐pop
Number of subjects: 40

Group type: COMPARATOR
Intervention: Phosphoric acid + Transbond XT primer
Number of subjects: 40
Study: 14509861

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural stress management/expressive supportive therapy (CBSM+) intervention
Number of subjects: 174

Group type: COMPARATOR
Intervention: Individual control condition
Number of subjects: 174
Study: 11002624

Group type: EXPERIMENTAL
Intervention: subsyde-CR (diclofenac in controlled release formulation using DRCM technology)
Number of subjects: 0

Group type: COMPARATOR
Intervention: meloxicam (standard formulation)
Number of subjects: 0
Study: 8946307

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 156911

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 156911
Study: 1430680

Group type: EXPERIMENTAL
Intervention: Holter monitoring with ST segment depression
Number of subjects: 109

Group type: COMPARATOR
Intervention: Holter monitoring without ST segment depression
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) treatment
Number of subjects: 109
Study: 3907334

Group type: EXPERIMENTAL
Intervention: High-nitrogen, low-carbohydrate diet (experimental diet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isocaloric control diet (control group)
Number of subjects: 12
Study: 30693366

Group type: EXPERIMENTAL
Intervention: Collegial discussions on patient cases (two 3-hour seminars)
Number of subjects: 69
Study: 30672177

Group type: EXPERIMENTAL
Intervention: Grain-moxibustion combined with acupuncture
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 88
Study: 26633836

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg bid for seven days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23975053

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxin A (Vistabel®)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 22341062

Group type: EXPERIMENTAL
Intervention: ProTaper Universal System
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SybronEndo K3 System
Number of subjects: 40

Group type: COMPARATOR
Intervention: H-files
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 19789433

Group type: EXPERIMENTAL
Intervention: Comprehensive directed breathing retraining
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional diaphragmatic breathing
Number of subjects: 24
Study: 18034990

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol for sedation
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Moderate sedation (OAA/S score of 3)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Higher sedation levels
Number of subjects: 250
Study: 16130506

Group type: EXPERIMENTAL
Intervention: Oral disodium pamidronate combined with calcium salts and vitamin D3 supplements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium salts and vitamin D3 supplements alone
Number of subjects: 0
Study: 12193919

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (800 microg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surgical therapy (dilatation and curettage)
Number of subjects: 50
Study: 10206802

Group type: EXPERIMENTAL
Intervention: Dodecafluoropentane
Number of subjects: 16
Study: 7771602

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG powder sprinkled on flavored gelatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2126114

Group type: EXPERIMENTAL
Intervention: 7 or more days of metronidazole and cefazolin prophylaxis
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2 days of metronidazole and cefazolin prophylaxis
Number of subjects: 50
Study: 368533

Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31529047

Group type: EXPERIMENTAL
Intervention: T1D with previous preeclampsia (T1D+/PE+; n = 28)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: T1D without preeclampsia (T1D+/PE-; n = 28)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Previous preeclampsia without T1D (T1D-/PE+; n = 28)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Controls without T1D or PE (T1D-/PE-; n = 28)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: T1D+/PE- or T1D-/PE+
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: T1D+/PE+
Number of subjects: 112
Study: 30028021

Group type: EXPERIMENTAL
Intervention: High-fluoride dentifrice (5,000 ppm fluoride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dentifrice (1,450 ppm fluoride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher income and more years of formal education
Number of subjects: 0
Study: 27891702

Group type: EXPERIMENTAL
Intervention: Cancer-PEPSONE programme (CPP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Support as usual (control)
Number of subjects: 35
Study: 26049727

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 206

Group type: COMPARATOR
Intervention: Conventional diuretics
Number of subjects: 206
Study: 24268031

Group type: EXPERIMENTAL
Intervention: Laparoscopic Burch colposuspension (LBC)
Number of subjects: 96
Study: 20814410

Group type: EXPERIMENTAL
Intervention: DAG oil (15% of total caloric intake, mean intake 33.0 ± 3.1 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAG oil (15% of total caloric intake, mean intake 33.0 ± 3.1 g/day)
Number of subjects: 0
Study: 19486955

Group type: EXPERIMENTAL
Intervention: IC51 (Japanese Encephalitis vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAVRIX1440 (hepatitis A vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant vaccination (IC51 and HAVRIX1440)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single vaccination (IC51 or HAVRIX1440)
Number of subjects: 0
Study: 17113441

Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split osteotomy (BSSO) only, with or without genioplasty; BSSO + Le Fort I, with or without genioplasty
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: BSSO + Le Fort I
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Genioplasty
Number of subjects: 146
Study: 15522050

Group type: EXPERIMENTAL
Intervention: (99m)Tc-sestamibi during exercise
Number of subjects: 31

Group type: COMPARATOR
Intervention: (99m)Tc-sestamibi during dipyridamole stress testing
Number of subjects: 31
Study: 11748390

Group type: EXPERIMENTAL
Intervention: 10 mg spinal ropivacaine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 15 mg spinal ropivacaine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 20 mg spinal ropivacaine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 25 mg spinal ropivacaine
Number of subjects: 72
Study: 9284668

Group type: EXPERIMENTAL
Intervention: Placebo (withdrawal group, n = 102)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Continuation of diuretic treatment (control group, n = 100)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Placebo (withdrawal group)
Number of subjects: 202
Study: 8141716

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy administered within six hours of symptom onset
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public education on symptoms of myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expeditious transfer to hospital and assessment
Number of subjects: 0
Study: 2881565

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 30
Study: 31549623

Group type: EXPERIMENTAL
Intervention: Test (generic formulation)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Reference (branded formulation)
Number of subjects: 64
Study: 30515480

Group type: EXPERIMENTAL
Intervention: 6.6‐mm long implants
Number of subjects: 60

Group type: COMPARATOR
Intervention: 9.6‐mm or longer implants (augmented group)
Number of subjects: 60
Study: 27342654

Group type: EXPERIMENTAL
Intervention: TGP 1800 mg/day and losartan 100 mg/day for 6 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Losartan 100 mg/day for 6 months
Number of subjects: 76
Study: 25410510

Group type: EXPERIMENTAL
Intervention: Web-based assessment
Number of subjects: 229

Group type: COMPARATOR
Intervention: In-person follow-up
Number of subjects: 229
Study: 22624409

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic training (3 weeks, 2 times a week, 21 minutes per session)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Group E1 (workload at 45% to 65% of individual VO2max)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Group E2 (workload based on subjective evaluation of exertion, marked 4-6)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Subjective assessment of exertion during training
Number of subjects: 18
Study: 20026256

Group type: EXPERIMENTAL
Intervention: Nanosomal Tacrolimus (5 mg/kg in rats, 10 mg/kg in mice)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nanosomal Tacrolimus
Number of subjects: 2

Group type: COMPARATOR
Intervention: Marketed HCO‐60 based Tacrolimus
Number of subjects: 2
Study: 17572412

Group type: EXPERIMENTAL
Intervention: Crinone 8% intravaginal gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular progesterone (IMP)
Number of subjects: 0
Study: 15618441

Group type: EXPERIMENTAL
Intervention: Early supported discharge and continued rehabilitation at home (ESD)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 83
Study: 12614602

Group type: EXPERIMENTAL
Intervention: Infant massage by the mother
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10028925

Group type: EXPERIMENTAL
Intervention: Azelnidipine (8.0 mg once daily for 4 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7567425

Group type: EXPERIMENTAL
Intervention: High visibility gratings with varying orientation, spatial frequency, and contrast
Number of subjects: 216

Group type: COMPARATOR
Intervention: Single parameter variation (orientation, spatial frequency, or contrast)
Number of subjects: 216
Study: 1975187

Group type: EXPERIMENTAL
Intervention: Esmolol 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Esmolol 200 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7337792

Group type: EXPERIMENTAL
Intervention: Study treatment assigned to private physicians (specific treatment details not available)
Number of subjects: 0
Study: 30157976

Group type: EXPERIMENTAL
Intervention: PoNDER health visitor training
Number of subjects: 2241

Group type: COMPARATOR
Intervention: Control group (no PoNDER HV training)
Number of subjects: 2241
Study: 28233012

Group type: EXPERIMENTAL
Intervention: Supervised structured exercise programme (aerobic and resistance exercises performed bi-weekly, plus at least 30 min of brisk daily walks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard antenatal care (control group)
Number of subjects: 45
Study: 26347110

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin 25 mg patches for 2 days before, the day of, and 2 days after each chemotherapy infusion.
Number of subjects: 372

Group type: COMPARATOR
Intervention: Control group (no nitroglycerin).
Number of subjects: 372
Study: 23955552

Group type: EXPERIMENTAL
Intervention: Intermittent tri-weekly docetaxel (75 mg m(‐2) once tri-weekly) plus bicalutamide (50 mg once daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continuous docetaxel without bicalutamide
Number of subjects: 42
Study: 22338852

Group type: EXPERIMENTAL
Intervention: Double-balloon colonoscopy (DBC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 58
Study: 19815876

Group type: EXPERIMENTAL
Intervention: Artesunate (AS) at 0.5 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Artesunate (AS) at 1 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Artesunate (AS) at 2 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Artesunate (AS) at 4 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Artesunate (AS) at 8 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin (DHA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Artesunate (AS)
Number of subjects: 40
Study: 17174729

Group type: EXPERIMENTAL
Intervention: Alkaline thermal water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alkaline, chlorine-containing mineral water
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 10
Study: 15342295

Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (stenting and bypass grafting)
Number of subjects: 0
Study: 11568036

Group type: EXPERIMENTAL
Intervention: Hypothermic group (34 degrees C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (37 degrees C)
Number of subjects: 0
Study: 9781417

Group type: EXPERIMENTAL
Intervention: Molsidomine (generic tablet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Molsidomine (reference product)
Number of subjects: 0
Study: 7816517

Group type: EXPERIMENTAL
Intervention: Intravenous fructose (200 mg/kg, 20% solution, 2.5 min)
Number of subjects: 12
Study: 3045842

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 124

Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Zolpidem 20 mg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 28977344

Group type: EXPERIMENTAL
Intervention: Low serum 25-hydroxyvitamin D (25OHD) levels
Number of subjects: 5607

Group type: EXPERIMENTAL
Intervention: Low serum 25-hydroxyvitamin D (25OHD) levels in women
Number of subjects: 5607

Group type: EXPERIMENTAL
Intervention: Low serum 25-hydroxyvitamin D (25OHD) levels in men
Number of subjects: 5607
Study: 28044135

Group type: EXPERIMENTAL
Intervention: ECVVH treatment for 72 hours
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard therapies without ECVVH
Number of subjects: 51
Study: 24756361

Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg oxycodone (OXY)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg oxycodone and 0.035 mg/kg naloxone solution (sOXN)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 24
Study: 23270636

Group type: EXPERIMENTAL
Intervention: Artesunate/Amodiaquine (AS+AQ) (Camoquin-Plus Paediatric®)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Artemether/Lumefantrine (AL) (Coartem®)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Both AS+AQ and AL
Number of subjects: 481
Study: 21044908

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 1197
Study: 18551200

Group type: EXPERIMENTAL
Intervention: Fluticasone 250 microg/salmeterol 50 microg (F/S)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluticasone 250 microg/salmeterol 50 microg plus montelukast 10 mg (F/S + M)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study: 15867282

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopheryl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: all-rac-alpha-tocopheryl acetate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both RRR and all-rac treatments
Number of subjects: 10
Study: 12906020

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneously twice a week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study: 10690146

Group type: EXPERIMENTAL
Intervention: Oxygen administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 20
Study: 8942325

Group type: EXPERIMENTAL
Intervention: Paracetamol 1.5 g
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of paracetamol 1.5 g and diclofenac 100 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 1777736

Group type: EXPERIMENTAL
Intervention: ABMT
Number of subjects: 45

Group type: COMPARATOR
Intervention: MSI
Number of subjects: 45

Group type: COMPARATOR
Intervention: AFSI
Number of subjects: 45
Study: 7468959

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing of nitrous oxide, oxygen and halothane
Number of subjects: 2

Group type: COMPARATOR
Intervention: Mechanical ventilation with fentanyl and alcuronium
Number of subjects: 2
Study: 30523029

Group type: EXPERIMENTAL
Intervention: SGLT2i users
Number of subjects: 1418

Group type: EXPERIMENTAL
Intervention: Dapagliflozin users
Number of subjects: 1418
Study: 29444699

Group type: EXPERIMENTAL
Intervention: Intracervically administered terlipressin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 27510521

Group type: EXPERIMENTAL
Intervention: Voriconazole 400 mg twice daily on the first day and 200 mg twice daily thereafter
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23823711

Group type: EXPERIMENTAL
Intervention: Core stabilisation training and traditional arm rehabilitation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Traditional arm rehabilitation alone
Number of subjects: 27
Study: 22672917

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy plus an oral care protocol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care (oral care protocol alone)
Number of subjects: 46
Study: 19560157

Group type: EXPERIMENTAL
Intervention: Abdominal radiography interpreted by pediatric emergency physicians
Number of subjects: 100
Study: 17313289

Group type: EXPERIMENTAL
Intervention: Training 2 times per week, 3 sets of 10 repetitions to fatigue for 9 exercises
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Training 3 times per week, 2 sets of 10 repetitions to fatigue for 9 exercises
Number of subjects: 29
Study: 15049152

Group type: EXPERIMENTAL
Intervention: 30 mg lycopene (Tomatol) per day during 24 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39